阿德福韦酯联合拉米夫定对乙型肝炎肝硬化失代偿期抗病毒效应的疗效对比

表2 两组患者治疗前后HCV DNA水平、肝功能改善及Child-Pugh评分的比较 (n = 20)

分组	时间	ALT (U/L)	TBiL (μmol/L)	Alc (g/L)	Child-Pugh评分	HCV DNA log10 (拷贝/mL)
观察组	治疗前	122.4 ± 25.2	48.1 ± 14.9	30.1 ± 3.0	11.0 ± 1.29	6.20 ± 1.02
	治疗4 wk后	111.9 ± 21.2a	45.1 ± 15.1a	30.0 ± 2.9	9.79 ± 2.5	5.20 ± 1.10
	治疗12 wk后	105.1 ± 17.9a	40.9 ± 12.1a	31.0 ± 1.9a	10.3 ± 1.39	4.70 ± 1.47c
	治疗24 wk后	88.7 ± 17.9ac	37.0 ± 10.1ac	32.0 ± 2.0ac	9.7 ± 1.109c	3.73 ± 1.23c
	治疗48 wk后	48.1 ± 11.9ac	30.0 ± 6.4ac	35.2 ± 1.9ac	7.4 ± 1.19ac	3.32 ± 1.83c
对照组	治疗前	268.7 ± 43.0	71.0 ± 15.9	27.8 ± 1.49	10.2 ± 1.3	6.43 ± 1.0
	治疗4 wk后	248.9 ± 31.9c	67.0 ± 11.9	27.9 ± 2.49c	10.79 ± 1.1	5.32 ± 4.01c
	治疗12 wk后	218.9 ± 36.1	60.0 ± 14.1	27.9 ± 2.0	10.2 ± 1.0	4.90 ± 1.30
	治疗24 wk后	177.1 ± 42.0c	53.0 ± 14.1c	29.1 ± 2.0c	9.3 ± 1.2c	4.40 ± 1.23c
	治疗48 wk后	106.3 ± 29.1c	49.4 ± 18.2c	31.2 ± 1.8c	8.4 ± 1.2c	3.79 ± 1.01c

^aP<0.05 vs 对照组;

^cP<0.05 vs 本组治疗前. HCV: 丙型肝炎病毒; ALT: 谷丙转氨酶; TBiL: 总胆红素.